On November 22, 2024, BRL Medicine Inc. announced the completion of nearly 200 million yuan in B+ round financing. The round was led by CSCP Fund, with follow-on investments from institutions including Beta Fund. With this funding, BRL Medicine will accelerate the clinical translation and commercialization of its multi-pipeline products and enhance its global R&D efforts, contributing to the advancement of life sciences and offering hope to patients with genetic diseases, malignant tumors, and autoimmune diseases worldwide.
Industry Leader in Cell and Gene Therapy
As a leading cell and gene therapy company, BRL Medicine has been committed to the basic research and development of innovative drugs. The company relies on the deep academic foundation of its core team to explore gene editing applications, establish a robust patent portfolio, and transform research outcomes into a potential commercial product pipeline. Currently, four projects have received IND approval and officially entered the registration clinical trial phase, with several others in the IND application stage.
Progress and Achievements in Clinical Trials
BRL-101, a gene therapy product for Transfusion dependent beta-Thalassemia, is the world’s first project to successfully treat severe beta0/beta0 thalassemia through gene editing technology, demonstrating optimal clinical outcomes. BRL-201, a CD19-targeted non viral site-specific integration PD1-CAR-T cell product, Representatives a revolutionary innovation in non viral CAR-T technology, offering reduced costs, shorter preparation times, and superior clinical outcomes. BRL-203, based on non viral fixed-point integration PD1-CAR-T, Recently received IND approval for the treatment of moderate to severe refractory systemic lupus erythematosus (SLE). Additionally, BRL-301, a UCAR-T product for B-cell malignancies, and BRL-303, an allogenetic universal CAR-T for autoimmune diseases, have shown significant industrialization advantages and have been published in prestigious journals including Cell.
Global Recognition and Milestones
BRL Medicine’s research achievements have been published in top-tier journals such as Nature, Cell, Nature Medicine, and Nature Biotechnology, and have been presented at international conferences like ASH, ASGCT, SITC, and EHA. The company is entering a phase of concentrated milestones, with years of experience in the CGT field, establishing itself as a global leader in gene and cell therapy.
Investor Confidence and Support
Shi Yao Fund, the lead investor, expressed confidence in BRL Medicine’s development prospects, highlighting the company’s global leading position in cell and gene therapy, top-tier scientific team, and advanced technology. Beta Fund, as a follow-on investor, also看好 BRL Medicine’s development potential, emphasizing the company’s significant position in the industry and its continuous innovation in technology development.
About BRL Medicine Inc.
Shanghai BRL Medicine is dedicated to becoming a leading global cell and gene therapy company in the new commercial civilization era. With a mission to “lead innovation with gene editing technology and develop breakthrough therapies to benefit all of humanity,” BRL Medicine has generated over 100 patent outcomes and initiated clinical trials in over 20 renowned hospitals. The company has established five proprietary technology platforms and operates a 7000-square-meter GMP pilot base with a team of nearly 100, ensuring rapid translation and application of innovative research results. BRL Medicine continuously drives rapid product updates based on patient needs and clinical feedback and collaborates with global innovative biopharmaceutical companies to accelerate the transformation and implementation of innovative drugs, benefiting patients worldwide.-Fineline Info & Tech
Leave a Reply